Olanzapine

Download image
Mode of action
Olanzapine
Transporter zone
No interaction
Enzyme zone
No interaction
Receptor zone
Contributes to other effects
Important for clinical effects
Important for clinical effects
Contributes to other effects
Important for clinical effects
Ion channel zone
No interaction
References
  1. Kroeze, W. K., S. J. Hufeisen, B. A. Popadak, S. M. Renock, S. Steinberg, P. Ernsberger, K. Jayathilake, H. Y. Meltzer and B. L. Roth (2003). "H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs." Neuropsychopharmacology 28(3): 519-526.
  2. Mamo, D., S. Kapur, M. Keshavan, M. Laruelle, C. C. Taylor, P. A. Kothare, P. Barsoum and D. McDonnell (2008). "D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia." Neuropsychopharmacology 33(2): 298-304.
  3. Shahid, M., G. B. Walker, S. H. Zorn and E. H. Wong (2009). "Asenapine: a novel psychopharmacologic agent with a unique human receptor signature." J. Psychopharmacol 23(1): 65-73.

For more detailed explanation of the principles of the VM Library

Please notice that Caution should be applied when extrapolating animal data to humans.

Detailed and Approved Information on the clinical use of the compounds can be found at the homepage of EMA or at Martindale.

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind